We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MDT enters fiscal 2027 with 6.75%-7.25% organic growth guidance and EPS between $5.9 and $6.00.
MDT trades at 13.7x forward earnings, below peers and its own 5-year median of 15.8x.
Cardiac Ablation Solutions grew 78% worldwide, while tariffs add about $250M cost headwind for MDT.
Medtronic plc (MDT - Free Report) enters fiscal 2027 with guidance calling for continued organic growth and modest adjusted earnings expansion. At roughly the mid-teens on forward earnings and with a 3.5% dividend yield, the setup can appeal to investors seeking steadier medical-device exposure.
The long-term stance is Neutral because progress in growth platforms is being weighed against near-term headwinds. Tariffs, fuel and transportation costs, mix drag, currency exposure and competition remain the main checks on upside.
MDT Setup: Guidance Points Up, but Risks Persist
For fiscal 2027, Medtronic guided for organic revenue growth of 6.75% to 7.25% and adjusted earnings per share of $5.90 to $6.00. The outlook includes a 53rd week and a full-year contribution from the Diabetes business while separation plans remain on track.
Consensus expectations call for fiscal 2027 revenue of $38.62 billion and earnings per share of $5.96. With guidance and consensus close, the decision hinges on whether execution can hold up as costs and mix pressure the model.
Image Source: Zacks Investment Research
Medtronic Valuation vs Peers and Its Own History
MDT trades at 13.7 times forward 12-month earnings versus 15.5 times for the Zacks sub-industry, 19.9 times for the Zacks sector and 21.5 times for the S&P 500. The discount suggests investors want clearer margin traction before paying up.
Over the past five years, the stock has traded between 12.1 times and 22.9 times, with a median of 15.8 times. The $86 price target assumes 14.4 times forward earnings, implying only modest multiple support.
Image Source: Zacks Investment Research
MDT What’s Working: CAS, CRM, and Procedure Demand
Procedure-driven demand has been resilient. Fourth-quarter fiscal 2026 revenue rose 9.9% year over year to $9.81 billion and topped expectations as volumes stayed firm.
Cardiac Ablation Solutions is the clearest growth driver, with sales up 78% worldwide and 124% in the United States, supported by Affera and Sphere-9 adoption. Cardiac Rhythm Management grew in the mid-single digits, supported by Micra, Aurora EV-ICD and OmniaSecure, keeping cardiovascular momentum constructive.
Medtronic What’s Not: Mix, Coronary, and U.S. Variability
Structural Heart has been uneven in the United States. The category was flat in the fourth quarter, and softer U.S. performance contributed to the variability in the outlook.
Coronary declined, and stents fell into the low double digits due to multi-region pricing declines. Medical Surgical also faces bariatric and advanced stapling weakness tied to the shift toward robotic surgery, which can pressure mix and leverage.
MDT Margin and Cost Headwinds to Underwrite
Fourth-quarter fiscal 2026 margins were mixed. Adjusted gross margin improved 30 basis points to 65.4%, but adjusted operating margin fell 230 basis points to 25.5% amid notable headwinds, including tariffs.
For fiscal 2027, management expects about $250 million of tariff impact to cost of goods sold, up $65 million year over year, plus roughly a one-point earnings drag from higher fuel and transportation costs. Gross margin is expected to decline about 20 basis points, including tariffs, making “can growth outpace cost drag” the key question.
Medtronic Balance Sheet and Shareholder Returns Matter
Medtronic ended fiscal 2026 with $9.2 billion in cash and investments. It issued $1.75 billion of long-term debt and repaid $2.93 billion, and generated $7.33 billion of operating cash flow and $5.43 billion of free cash flow.
The company returned $4.2 billion to shareholders in fiscal 2026 and raised the quarterly dividend to $0.72 for the first quarter of fiscal 2027, marking the 49th consecutive year of dividend increases. That capacity supports both tuck-in deals and ongoing returns.
MDT Short-Term Signal: What the Rank Implies
MDT carries a Zacks Rank #4 (Sell), with Style Scores of Value: C, Growth: D, Momentum: C and VGM: C. The signal points to weaker near-term sentiment and revision dynamics despite longer-cycle product catalysts.
Investors may see the platform story, but the short-term signal suggests the market wants proof that margins and weaker categories are improving before rewarding the stock.
Medtronic Decision Framework: Who MDT Fits Now
MDT may suit investors prioritizing income and steadier medical-device exposure with identifiable growth platforms, including Cardiac Ablation Solutions, Symplicity Spyral, Hugo robotic-assisted surgery and Neuroscience innovations such as Stealth AXiS and Neuroguard.
The tradeoff is that tariffs, currency sensitivity, competition, and mix and coronary pressures may limit near-term valuation upside. Investors weighing alternatives may also compare Abbott Laboratories (ABT - Free Report) and Stryker Corporation (SYK - Free Report) as different ways to gain procedure-driven exposure. For MDT, patience may be required until costs and mix stabilize.
View the Zacks #1 Rank List
Image: Bigstock
Is Medtronic Stock a Buy at 14x Forward Earnings?
Key Takeaways
Medtronic plc (MDT - Free Report) enters fiscal 2027 with guidance calling for continued organic growth and modest adjusted earnings expansion. At roughly the mid-teens on forward earnings and with a 3.5% dividend yield, the setup can appeal to investors seeking steadier medical-device exposure.
The long-term stance is Neutral because progress in growth platforms is being weighed against near-term headwinds. Tariffs, fuel and transportation costs, mix drag, currency exposure and competition remain the main checks on upside.
MDT Setup: Guidance Points Up, but Risks Persist
For fiscal 2027, Medtronic guided for organic revenue growth of 6.75% to 7.25% and adjusted earnings per share of $5.90 to $6.00. The outlook includes a 53rd week and a full-year contribution from the Diabetes business while separation plans remain on track.
Consensus expectations call for fiscal 2027 revenue of $38.62 billion and earnings per share of $5.96. With guidance and consensus close, the decision hinges on whether execution can hold up as costs and mix pressure the model.
Image Source: Zacks Investment Research
Medtronic Valuation vs Peers and Its Own History
MDT trades at 13.7 times forward 12-month earnings versus 15.5 times for the Zacks sub-industry, 19.9 times for the Zacks sector and 21.5 times for the S&P 500. The discount suggests investors want clearer margin traction before paying up.
Over the past five years, the stock has traded between 12.1 times and 22.9 times, with a median of 15.8 times. The $86 price target assumes 14.4 times forward earnings, implying only modest multiple support.
Image Source: Zacks Investment Research
MDT What’s Working: CAS, CRM, and Procedure Demand
Procedure-driven demand has been resilient. Fourth-quarter fiscal 2026 revenue rose 9.9% year over year to $9.81 billion and topped expectations as volumes stayed firm.
Cardiac Ablation Solutions is the clearest growth driver, with sales up 78% worldwide and 124% in the United States, supported by Affera and Sphere-9 adoption. Cardiac Rhythm Management grew in the mid-single digits, supported by Micra, Aurora EV-ICD and OmniaSecure, keeping cardiovascular momentum constructive.
Medtronic What’s Not: Mix, Coronary, and U.S. Variability
Structural Heart has been uneven in the United States. The category was flat in the fourth quarter, and softer U.S. performance contributed to the variability in the outlook.
Coronary declined, and stents fell into the low double digits due to multi-region pricing declines. Medical Surgical also faces bariatric and advanced stapling weakness tied to the shift toward robotic surgery, which can pressure mix and leverage.
MDT Margin and Cost Headwinds to Underwrite
Fourth-quarter fiscal 2026 margins were mixed. Adjusted gross margin improved 30 basis points to 65.4%, but adjusted operating margin fell 230 basis points to 25.5% amid notable headwinds, including tariffs.
For fiscal 2027, management expects about $250 million of tariff impact to cost of goods sold, up $65 million year over year, plus roughly a one-point earnings drag from higher fuel and transportation costs. Gross margin is expected to decline about 20 basis points, including tariffs, making “can growth outpace cost drag” the key question.
Medtronic Balance Sheet and Shareholder Returns Matter
Medtronic ended fiscal 2026 with $9.2 billion in cash and investments. It issued $1.75 billion of long-term debt and repaid $2.93 billion, and generated $7.33 billion of operating cash flow and $5.43 billion of free cash flow.
The company returned $4.2 billion to shareholders in fiscal 2026 and raised the quarterly dividend to $0.72 for the first quarter of fiscal 2027, marking the 49th consecutive year of dividend increases. That capacity supports both tuck-in deals and ongoing returns.
MDT Short-Term Signal: What the Rank Implies
MDT carries a Zacks Rank #4 (Sell), with Style Scores of Value: C, Growth: D, Momentum: C and VGM: C. The signal points to weaker near-term sentiment and revision dynamics despite longer-cycle product catalysts.
Investors may see the platform story, but the short-term signal suggests the market wants proof that margins and weaker categories are improving before rewarding the stock.
Medtronic Decision Framework: Who MDT Fits Now
MDT may suit investors prioritizing income and steadier medical-device exposure with identifiable growth platforms, including Cardiac Ablation Solutions, Symplicity Spyral, Hugo robotic-assisted surgery and Neuroscience innovations such as Stealth AXiS and Neuroguard.
The tradeoff is that tariffs, currency sensitivity, competition, and mix and coronary pressures may limit near-term valuation upside. Investors weighing alternatives may also compare Abbott Laboratories (ABT - Free Report) and Stryker Corporation (SYK - Free Report) as different ways to gain procedure-driven exposure. For MDT, patience may be required until costs and mix stabilize.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.